Teva Pharmaceutical Industries Limited (TLV:TEVA)
12,000
-160 (-1.32%)
Oct 5, 2026, 5:28 PM IDT
Teva Pharmaceutical Industries Employees
As of December 31, 2025, Teva Pharmaceutical Industries had 32,842 total employees, including 31,173 full-time and 1,669 part-time employees. The number of employees decreased by 2,844 or -7.97% compared to the previous year.
Employees
32,842
Change
-2,844
Growth
-7.97%
Revenue / Employee
1.61M ILS
Profits / Employee
65.71K ILS
Market Cap
141.24B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 32,842 | -2,844 | -7.97% | 31,173 | 1,669 |
| Jun 30, 2025 | 37,000 | 0 | - | 37,000 | 0 |
| Mar 31, 2025 | 37,000 | 528 | 1.45% | 37,000 | 0 |
| Dec 31, 2024 | 35,686 | -786 | -2.16% | 33,892 | 1,794 |
| Sep 30, 2024 | 37,000 | 528 | 1.45% | 37,000 | 0 |
| Dec 31, 2023 | 36,472 | 1,347 | 3.83% | 35,001 | 1,471 |
| Dec 31, 2022 | 35,125 | -854 | -2.37% | 34,004 | 1,121 |
| Dec 31, 2021 | 35,979 | -2,393 | -6.24% | 34,713 | 1,266 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Amal Holdings A.D. | 30,248 |
| Danel (Adir Yeoshua) | 4,288 |
| Novolog (Pharm-Up 1966) | 916 |
| Kamada | 462 |
| InterCure | 285 |
| Rafa Laboratories | 257 |
| Bait Bakfar | 244 |
| Ilex Medical | 181 |
Teva Pharmaceutical Industries News
- 3 days ago - Teva announces published review on dopamine pathways in Tourette syndrome - TheFly
- 3 days ago - Teva announces new data for ecopipam - TheFly
- 3 days ago - Journal of Child Neurology Publishes Review Highlighting Dopamine's Role in Tourette Syndrome and Ecopipam's Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients - GlobeNewsWire
- 3 days ago - Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome - GlobeNewsWire
- 4 days ago - Teva, Samsung Bioepis expand strategic partnership to advance biosimilars - TheFly
- 4 days ago - Teva initiated with a Buy at TD Cowen - TheFly
- 4 days ago - Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates - Business Wire
- 5 days ago - TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness - GlobeNewsWire